Physician profile
Kathy Bernstein
NPI 1144642091
$5,753.25
in general payments reported to CMS, 2019-2025
34 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 91% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $690 · 2023: $1,016 · 2024: $1,707 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,095 · Education: $87.50 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,095.39 |
| Education | $87.50 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $686.79 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $620.39 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $607.51 | 2022-2025 | Ozempic, Rybelsus |
| Beta Bionics, INC. | $589.88 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic, INC. | $480.09 | 2021-2024 | Minimed 780g |
| Lilly USA, LLC | $456.39 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Mannkind Corporation | $286.15 | 2023-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $267.26 | 2024-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $230.88 | 2022-2025 | |
| Insulet Corporation | $217.20 | 2022-2025 | Omnipod |
| Pfizer INC. | $170.97 | 2023-2025 | |
| Amgen INC. | $127.88 | 2023-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $121.95 | 2022-2025 | |
| Zealand Pharma US, INC. | $108.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.08 | 2024-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $78.84 | 2022 | |
| Ascendis Pharma Endocrinology INC | $73.21 | 2024-2025 | Yorvipath |
| Calliditas Therapeutics US INC. | $67.76 | 2022-2023 | Tarpeyo |
| Amneal Pharmaceuticals LLC | $62.59 | 2022-2025 | Unithroid |
| Esperion Therapeutics, INC. | $61.13 | 2023-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $60.11 | 2023-2024 | Farxiga, Lokelma |
| Regeneron Healthcare Solutions, INC. | $48.06 | 2023 | Dupixent |
| Ultragenyx Pharmaceutical INC. | $29.67 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $27.60 | 2025 | Neffy |
| Ardelyx, INC. | $25.07 | 2024 | Ibsrela |
| Genentech USA, INC. | $23.23 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.31 | 2024 | Eliquis |
| Kyowa Kirin, INC. | $19.96 | 2023 | Crysvita |
| Rhythm Pharmaceuticals, INC. | $19.50 | 2025 | Imcivree |
| Viatris Specialty LLC | $18.86 | 2025 | Yupelri |
| Verona Pharma, INC. | $16.79 | 2025 | Ohtuvayre |
| Amphastar Pharmaceuticals, INC. | $15.72 | 2024 | Baqsimi |
| Embecta Corp. | $15.40 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Merck Sharp & Dohme LLC | $13.49 | 2023 | Steglatro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.